• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Bivalent COVID-19 booster has a similar safety profile and efficacy at preventing infection as compared to previous vaccines

byGrace YinandKiera Liblik
October 7, 2022
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The bivalent omicron-containing coronavirus 2019 disease (COVID-19) vaccine has a similar safety profile to previous mRNA vaccinations. 

2. The bivalent vaccine also elicits a noninferior immunogenic response as compared to previously approved vaccines.

Evidence Rating Level: 2 (Good)

Study Rundown: The emergence of COVID-19 variants conferring increased immunologic escape or transmissibility compared to ancestral COVID-19 has prompted the development of new booster vaccines. The bivalent vaccine contains equal parts spike proteins against both the omicron variant BA.1 and the ancestral COVID-19 strain. The present study compared the bivalent vaccine to the original booster vaccine in adults who have had two doses of primary vaccination and a first booster dose. It primarily aimed to understand the bivalent vaccine’s safety profile and the bivalent vaccine’s ability to elicit neutralizing antibody responses compared to the original COVID-19 vaccine. Results found that the bivalent vaccine had a similar safety profile to the original booster vaccine against COVID-19 without any additional serious adverse reactions, fatal reactions, or severe reactions requiring discontinuation of the study. The bivalent vaccine also elicited enough neutralizing antibody responses within participants who received it to be considered noninferior to the original booster vaccine against COVID-19. The major limitations of this study were that it was not randomized, the follow-up time was limited, and vaccine efficacy was not fully assessed. This study provided evidence of an acceptable safety profile and immunogenicity reaction of the bivalent vaccine.

Click to read the study in NEJM

In-Depth [open-label trial]: The current study was an open-label, phase 2 to 3 study evaluating the safety profile, immunogenicity, and reactogenicity of 50-ug of the bivalent Omicron-containing vaccine (mRNA-1273.214). Follow-up was done at 28-days and it was administered as a second booster dose for adults who had completed a two-dose primary series. Participants with a prior known history of infection 3-months prior were excluded. Of the 819 participants, 437 were assigned to receive the bivalent vaccine, and 377 were assigned to receive the mRNA-1273 vaccine as a second booster dose. The primary objectives were to evaluate adverse reactions 28-days after booster administration. Primary results of the safety analysis found that injection-site pain, fatigue, headache, myalgia, and arthralgia were the most frequently reported adverse reactions. The incidence of these was similar between the bivalent vaccine and mRNA-1273 vaccine groups. No serious adverse reactions considered related to study vaccination were reported, and no fatal reactions were reported. Two participants each from the bivalent vaccine group (0.5%) and the mRNA-1273 group (0.5%) experienced systemic adverse reactions requiring medical attention (hypertension and urticaria). Primary results of the immunogenicity analysis found an estimated adjusted geometric mean titer ratio between the bivalent booster and mRNA-1273 booster of 1.22 (97.5% Confidence Interval [CI], 1.08 to 1.37) against ancestral SARS-Cov-2 and 1.75 (97.5% CI, 1.49-2.04) against omicron, satisfying noninferiority of the bivalent vaccine. In summary, the bivalent booster demonstrated similar efficacy and safety profiles to previous COVID-19 boosters.

Image: PD

RELATED REPORTS

Guidelines from many countries recommend physical activity during uncomplicated pregnancy

Wellness Check: Exercise

Nirmatrelvir-ritonavir combination reduces hospitalization and mortality in COVID-19

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Bivalent COVID-19 vaccineboosterCOVID-19COVID-19 Vaccineinfectious diseasemrna-1273omicronpublic healthvaccination
Previous Post

#VisualAbstract: Minocycline is not effective at reducing depressive symptoms in treatment-refractory depression

Next Post

Esketamine as an adjunct with propofol and fentanyl to avoid perioperative hypotension

RelatedReports

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity
Obstetrics

Guidelines from many countries recommend physical activity during uncomplicated pregnancy

February 3, 2023
Few older adolescents meet recommended levels of physical activity
Wellness

Wellness Check: Exercise

February 2, 2023
Ultrasound enhances gastrointestinal absorption of drugs at low frequencies
Emergency

Nirmatrelvir-ritonavir combination reduces hospitalization and mortality in COVID-19

February 1, 2023
Mental health parity law associated with financial protection for children
Endocrinology

Gender-affirming hormones improve psychosocial functioning in transgender youth

January 31, 2023
Next Post

Esketamine as an adjunct with propofol and fentanyl to avoid perioperative hypotension

Reduced gestational weight gain with lifestyle intervention

Diet, substance use, and physical activity and their effects on mental health outcomes

Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

2 Minute Medicine Rewind October 10, 2022

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options